CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,597 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02494297
NCT02494297N/ACompleted

Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries

Center for Epidemiology and Health Research, Germany·observational·Posted Jul 10, 2015·Updated Aug 27, 2021

In Brief

An observational study for Hirsutism and 4 related conditions. Completed, enrolled 1,597 participants across 1 site.

Detailed Summary

This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including: * prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol * use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label * concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives * second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesGermany
CollaboratorsBayer

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 10, 2015
Enrollment StartMar 6, 2015
Primary CompletionOct 31, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.0 years ago